Description

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. operates as a contract research organization (CRO) in China, primarily focused on the development of chemical and peptide-based pharmaceutical products. Its portfolio includes generic small-molecule chemical drugs and peptide therapies designed to treat a range of conditions such as impetigo, acne, renal anemia, hyperparathyroidism in chronic kidney disease patients on dialysis, and various pain-related ailments. Beyond drug development, the company offers a comprehensive array of research and evaluation services. These encompass testing for packaging material compatibility, detailed impurity profiling, extractables and leachables studies, and thorough safety assessments. Sun-Novo also provides support for consistency evaluations, facilitates clinical research, and delivers expert consulting and agency services for regulatory submissions. Furthermore, it conducts a full spectrum of GLP-compliant bioanalysis and pharmacokinetics-pharmacodynamics (PK/PD) studies, including pharmacokinetic, immunogenic, pharmacodynamic, and biomarker analyses. The company was founded in 2009 and is headquartered in Beijing, China.